申请人:Welfide Corporation
公开号:EP1081132A1
公开(公告)日:2001-03-07
Hydroxamic acid derivatives represented by general formula (I) or pharmacologically acceptable salts thereof; medicinal compositions containing the same and medicinal utilization thereof wherein each symbol has the meaning as defined in the specification. Because of having TNF-α production inhibitory effect, these derivatives or pharmacologically acceptable salts thereof are useful in preventing/treating autoimmune diseases and inflammatory diseases, for example, sepsis, MOF, rheumatoid arthritis, Crohn's disease, cachexia, myasthenia gravis, systemic lupus erythematosus, asthma, I type diabetes and psoriasis.
由通式(I)代表的羟肟酸衍生物或其药理学上可接受的盐;含有这些衍生物的药用组合物及其药用用途,其中各符号的含义如说明书中所定义。由于具有抑制 TNF-α 生成的作用,这些衍生物或其药理学上可接受的盐类可用于预防/治疗自身免疫性疾病和炎症性疾病,例如败血症、MOF、类风湿性关节炎、克罗恩病、恶病质、重症肌无力、系统性红斑狼疮、哮喘、I 型糖尿病和银屑病。